Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for treatment of COVID-19 pneumonia
ChiCTR2000029559Phase 4Recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (3 arms), sponsored by Renmin Hospital of Wuhan University. Primary endpoints: Time to negative SARS-CoV-2 nucleic acid test and T-cell recovery time. Started Jan 2020; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on ChiCTR2000029559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029559.